Lantern Pharma (LTRN) Change in Accured Expenses (2019 - 2026)

Lantern Pharma (LTRN) has 8 years of Change in Accured Expenses data on file, last reported at -$705025.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 4432.76% year-over-year to -$705025.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$417663.0 (down 219.27% YoY) and the FY2025 annual result came in at $271808.0, down 83.39% from the prior year.
• Change in Accured Expenses slipped to -$705025.0 in Q1 2026, from $466998.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q2 2022 to a low of -$2.1 million in Q3 2022.
• A 5-year average of $91023.6 and a median of $179074.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 1988.12% — and 2026, when it plunged 4432.76%.
• Tracing LTRN's Change in Accured Expenses over 5 years: stood at -$305639.0 in 2022, then surged by 237.39% to $419915.0 in 2023, then soared by 75.72% to $737880.0 in 2024, then tumbled by 36.71% to $466998.0 in 2025, then tumbled by 250.97% to -$705025.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$705025.0 (Q1 2026), $466998.0 (Q4 2025), and -$806921.0 (Q3 2025), per Business Quant data.